Tuesday, April 12, 2011
Targacept's drug compound TC-5619 has shown positive effects in improving cognitive functioning and negative symptoms in a Phase 2 trial of people diagnosed with schizophrenia. The company is actively developing plans to move forward with Astra Zeneca in bringing the drug to market.
Cl...
Encouraging news, to be sure. I think the industry is doing well on forging ahead with new medication and esp. long-term injectables. This is going to change a lot of lives. Now we wait five years here in Canada before we can use them with our consumers.
Don Fraser